

1 **DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy:**
2 **a meta-analysis and systematic review**

3

4 Zoe Phan^{1,2}, Caroline E. Ford³, C. Elizabeth Caldon^{1,2#}

5

6 1. The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW,
7 2010, Australia

8 2. St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales,
9 Sydney, NSW, 2052, Australia

10 3. School of Clinical Medicine, Faculty of Medicine and Health, University of New South
11 Wales, Sydney, NSW, 2052, Australia

12 # Corresponding author: l.caldon@garvan.org.au

13

14

15 **KEYWORDS:** PARP inhibitor, homologous recombination deficiency, chemotherapy,
16 combination therapy, BRCA1/2, SFLN11, survival, DNA repair

17 **WORD NUMBER: 5947**

18 **ACKNOWLEDGEMENTS:** We thank Dr Mark Donoghoe of Stats Central, Mark
19 Wainwright Analytical Centre, UNSW Sydney, for assistance with data extraction methods for
20 the meta-analysis. This research was generously supported by the Dr Lee MacCormick
21 Edwards Charitable Foundation. C.E.C. is supported by a Cancer Institute NSW Career
22 Development Fellowship (CDF1071).

23

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **ABSTRACT**

25 **Purpose**

26 The addition of PARP inhibitors to chemotherapy has been assessed in ~80 clinical trials across
27 multiple malignancies, on the premise that PARP inhibitors will increase chemotherapy
28 effectiveness regardless of whether cancers have underlying disruption of DNA repair
29 pathways. Consequently, the majority of combination therapy trials have been performed on
30 patients without biomarker selection, despite the use of homologous recombination deficiency
31 to dictate use of PARP inhibitors in the maintenance setting. An unresolved question is whether
32 biomarkers are needed to identify patients who respond to combination PARP inhibitors and
33 chemotherapy.

34

35 **Methods**

36 A systematic literature review identified studies using PARP inhibitors in combination with
37 chemotherapy versus chemotherapy alone, where the study included a biomarker of DNA
38 repair function (*BRCA1*, *BRCA2*, *BRCAPRO*, *ATM*, *ERCC1*, *SFLN11*). Hazard ratios (HR)
39 were pooled in a meta-analysis using generic inverse-variance and fixed or random effects
40 modelling. Subgroup analyses were conducted on biomarker selection and type of malignancy.

41

42 **Results**

43 Nine studies comprising 2,084 patients met the inclusion criteria. Progression-free survival
44 (PFS) was significantly better in patients with a DNA repair biomarker (HR 0.52, 95%
45 confidence interval (CI) 0.43-0.63; $p < 0.00001$), but there was no benefit in patients who
46 lacked a biomarker (HR 0.94, 95% CI 0.82–1.08; $p = 0.38$). Subgroup analysis showed that
47 *BRCA* mutation and *SFLN11* biomarkers could predict benefit, and biomarker-driven benefit

48 occurred in ovarian, breast and small cell lung cancers. The addition of PARP inhibitors was
49 associated with increased grade 3/4 side effects, and particularly neutropenia.

50

51 **Conclusions**

52 Combination therapy only increases PFS in patients with identifiable DNA repair biomarkers.
53 This indicates that PARP inhibitors do not sensitise patients to chemotherapy treatment, except
54 where their cancer has a homologous recombination defect, or an alternative biomarker of
55 altered DNA repair. While effective in patients with DNA repair biomarkers, there is a risk of
56 high-grade haematological side-effects with the use of combination therapy. Thus, the benefit
57 in PFS from combination therapy must be weighed against potential adverse effects, as
58 individual arms of treatment can also confer benefit.


59 **GRAPHICAL ABSTRACT**

60

61

62

**PARP INHIBITORS ONLY SHOW EVIDENCE OF SYNERGY WITH CHEMOTHERAPY
IN CANCERS WITH A DNA REPAIR BIOMARKER**




63

64 INTRODUCTION

65 Cancer places an enormous burden on our healthcare system as the leading cause of death
66 worldwide, accounting for nearly 10 million deaths in 2020 [1]. Targeted therapies and
67 personalised medicines are now demonstrating significant benefit in reducing cancer-
68 associated mortality [2]. Poly (ADP-ribose) polymerase (PARP)-inhibitors were introduced as
69 a targeted therapy in 2014, with initial approvals to treat cancers that had defects in homologous
70 recombination, such as mutations in the genes *BRCA1* and *BRCA2*. Alterations to homologous
71 recombination-related genes lead to a homologous recombination deficiency where cells are
72 unable to accurately repair DNA breaks and become overly reliant on other DNA repair
73 pathways, and particularly PARP-mediated repair. PARP inhibitors have also been investigated
74 in cancers with alterations in other DNA repair related genes [3]. When PARP is inhibited or
75 trapped on DNA in a cell with DNA repair deficiency, these cells rely on more error-prone
76 pathways of repair, and this leads to the accumulation of DNA damage and subsequent cell
77 death (Figure 1A).

78



79 **Figure 1. Schematic of how chemotherapy could potentiate PARP inhibition. In Panel A,**
80 **a cancer cell with homologous recombination deficiency (HRD) is sensitive to PARP**
81 **inhibitors because cells are unable to properly repair low level DNA damage, leading to**
82 **cancer cell death. Low level DNA damage is constantly generated by common**
83 **environmental exposures (UV, radiation) and endogenous DNA damage from oxidation**
84 **and DNA metabolism [4]. In Panel B, a cell with intact homologous recombination (HR)**
85 **is able to repair low level damage through homologous recombination, even in the**
86 **presence of PARP inhibitors. In Panel C, a cell with intact homologous recombination**
87 **may be sensitised to chemotherapy by inhibiting DNA repair with PARP inhibitors.**

88

89 Four PARP inhibitors are approved for clinical use as monotherapies: olaparib, rucaparib,
90 niraparib and talazoparib. Olaparib was first approved as a maintenance therapy for patients
91 with platinum-sensitive recurrent germline *BRCA*-mutated ovarian cancer who had a complete
92 or partial response to platinum-based chemotherapy [5]. Olaparib has since been approved for
93 HER2-negative, germline *BRCA*-mutated breast cancer, and a subset of pancreatic cancer
94 patients [6, 7]. In 2016, rucaparib was approved as a monotherapy for patients with advanced
95 ovarian cancer with either somatic or germline *BRCA* mutations [8]. In 2018, talazoparib was
96 approved for the treatment of deleterious germline *BRCA*-mutated, HER2-negative metastatic
97 breast cancer [9]. Niraparib has demonstrated benefit in ovarian cancer patients who have
98 previously responded to platinum chemotherapy, regardless of their homologous
99 recombination deficiency status [8, 10, 11] which has led to its approval in the maintenance
100 setting for newly diagnosed and recurrent ovarian cancers with platinum response. Additional
101 PARP inhibitors, such as veliparib, are currently being evaluated in clinical trials [12-16].

102

103 A critical aspect of PARP inhibitor usage is to accurately identify patients that will benefit from
104 these targeted therapies. The most common predictive biomarkers to indicate PARP inhibitor
105 sensitivity are mutations in the genes, *BRCA1* and *BRCA2*, which are essential in maintaining
106 genomic integrity. Identifying pathogenic *BRCA1/BRCA2* mutations can be further refined by
107 using genetic tests such as Myriad BRACAnalysis CDx, to determine germline *BRCA1/BRCA2*
108 mutations, or statistical models such as BRCAPRO, which incorporate family and individual
109 history of cancer diagnoses. Homologous recombination deficiency can also be driven by other
110 genomic changes including *BRCA1* methylation, or *PALB2/RAD51C/RAD51D* mutations [17].
111 However, these aberrations are not yet used clinically to identify patients for treatment with
112 PARP inhibitors. The presence of these mutations can give rise to characteristic genomic
113 rearrangements indicative of the loss of homologous recombination, which is often termed
114 “genomic scarring”. Genomic scars include loss of heterozygosity, large-scale translocations
115 and telomeric allelic imbalance. Next-generation sequencing-based assays such as myChoice
116 CDx can be used as an alternative or adjunct test to detect these genomic rearrangements and
117 identify homologous recombination deficient (HRD) patients within the clinic, and this
118 approach is commonly referred to as ‘HRD-score’ (**Table 1**).

119

120 New markers of altered DNA repair potential are also emerging (e.g. ATM, ERCC1, SLFN11)
121 and being assessed pre-clinically and in clinical trials. ATM is a key activator of the DNA
122 damage response to double-strand breaks and in pre-clinical models, loss/depletion of ATM
123 was shown to increase sensitivity of cells to PARP inhibitors in gastric, colorectal, lung and
124 pancreatic cancer [18]. Clinical trials are now assessing the benefit of PARP inhibitors in ATM-
125 deficient prostate and gastric cancer patients [19, 20]. ERCC1 is a key mediator of nucleotide
126 excision DNA repair, and it has been proposed that PARP inhibition increases sensitivity of
127 ERCC1-low non-small cell lung cancer cells to cisplatin [21]. SLFN11 is implicated in

128 replication fork stress and has been studied in several pre-clinical models of small cell lung
129 cancer where high SLFN11 expression strongly predicted cisplatin and PARP inhibitor
130 response [22-24].

131
132 Since the realisation of the clinical benefit of PARP inhibitors, a significant effort had been
133 made to expand their use to treat cancers without underlying DNA repair defects. Thus, a large
134 body of research has investigated whether there is synergy between PARP inhibitors and other
135 therapies, including chemotherapies. The premise for synergy is that excessive DNA damage
136 from chemotherapy will create too many DNA breaks and adducts to be repaired when PARP
137 is simultaneously inhibited, resulting in lethality (**Figure 1B**). This is hypothesised to occur
138 irrespective of defects in DNA repair [25-27].

139
140 Multiple preclinical *in vitro* and *in vivo* studies have demonstrated that synergy between PARP
141 inhibitors and chemotherapies can occur in the absence of identifiable DNA repair defects.
142 Several studies that combine PARP inhibitors with DNA alkylating agent temozolimide (TMZ)
143 have reported synergy: with niraparib across *in vitro* wildtype pheochromocytoma models [28],
144 with olaparib across *in vitro* and *in vivo* xenograft models of chordoma [29], with niraparib for
145 multiple myeloma [30], with veliparib in melanoma and glioma mouse models [31], and PARP
146 inhibitor GPI 15427 in combination with TMZ and CPT-11 colon cancer cell line models and
147 xenografts [32]. The addition of TMZ to PARP inhibitors is believed to increase cell death not
148 only by aggravating DNA damage, but also via increased PARP trapping [27, 33].

149
150 Topoisomerase I inhibitors (irinotecan and its active metabolite, SN-38) have also been
151 combined with PARP inhibitors to demonstrate anti-tumour effects in preclinical models.
152 Examples include with PARP inhibitors in *BRCAl/2* wildtype *in vitro* and xenograft models of

153 triple negative breast cancer [34], with niraparib across *in vivo* and *in vitro* models of colorectal
154 cancer without microsatellite instability [35], with veliparib in *in vitro* colon cancer models
155 [36], with olaparib in colon cancer cell lines *in vitro* and in xenografts [37], and with PARP
156 inhibitors in mouse leukemic cells [38].

157

158 Anti-tumour effects have also been elicited with combination of doxorubicin and olaparib in
159 2D and 3D ovarian cancer models [39], and between olaparib and a range of chemotherapies
160 in oesophageal squamous cell carcinoma cell lines [40]. Most recently, paclitaxel was
161 suggested to sensitise homologous recombination-proficient ovarian cancer cells to olaparib
162 [41]. By contrast Murai and colleagues reported that PARP inhibitors have little combinatorial
163 effect with cisplatin, but they synergise with camptothecin [33]. Studies of triplet treatment
164 with chemotherapy, irradiation and PARP inhibition has also shown promise in colorectal
165 cancer models [42].


166

167 This significant body of pre-clinical data has led to ~80 clinical trials to test PARP inhibitor
168 and chemotherapy combinations (see **Supplementary Table 1**) [43]. An assessment of these
169 trials shows that combination PARP inhibitors and chemotherapy has primarily been assessed
170 on unselected patient populations (**Figure 2**). In these trials only 22/79 (28%) included DNA
171 repair function as an inclusion criterion for patients entering the trial. Thus, the majority of
172 trials (72%; 57/79) do not require patients to have tumours with altered DNA repair status.
173 19/57 trials specify secondary analyses relating to DNA repair markers, however since these
174 trials mostly occur across cancer types with low penetrance of DNA repair defects, these may
175 not have accrued any cases with DNA repair alterations, or may not be sufficiently powered to
176 draw any conclusions. Of the fourteen clinical trials that are actively recruiting or preparing to
177 recruit patients, nine do not use DNA damage biomarkers as inclusion criteria, including trials

178 on gastric and small cell lung cancer (NCT05411679), relapsed paediatric acute myeloid
179 leukemia (NCT05101551), uterine leiomyosarcoma (NCT05432791), pancreatic cancer
180 (NCT05257993), advanced stage rare cancers (NCT05142241), leiomyosarcoma and renal cell
181 cancers (NCT04603365), breast cancer (NCT03150576), small cell cancers (NCT04209595),
182 and ewing sarcoma and rhabdomyosarcoma (NCT01858168).

183

184 Outcomes of combination trials have now been reported, allowing an assessment of whether
185 chemotherapy plus PARP inhibitor treatment generally improves outcome for patients.
186 Importantly there are now sufficient studies to assess whether any improvement in survival is
187 dependent on the presence of a DNA repair biomarker. Here, we provide the first synthesised
188 analysis of the benefit of PARP inhibitors plus chemotherapies across multiple malignancies.
189 Our study addresses whether the success of combination therapies in pre-clinical models
190 without DNA repair vulnerabilities translates to an improvement in outcome of all patients.



191

192 **Figure 2. Number of combination PARP inhibitor and chemotherapy clinical trials**
193 **selecting for DNA repair biomarker status and their year of initiation. 22/79 (28%)**
194 **clinical trials included DNA repair biomarkers as a selection criterion for patients**
195 **entering the trial and 57/79 (72%) clinical trials did not include DNA repair biomarkers**
196 **as a selection criterion. Search of these clinical trials was completed in August 2022. Full**
197 **details of trials are shown in Supplementary Table 1.**

198 **METHODS**

199 **PRISMA statement**

200 This meta-analysis was performed following the Preferred Reporting Items for Systematic
201 reviews and Meta-analysis (PRISMA) statement.

202

203 **Search strategies**

204 In October 2021, a systematic literature search of all English-language, phase II/III randomised
205 controlled trials was conducted on PubMed, EMBASE and Conference Proceedings Citation
206 Index – Science, with additional searches performed in August 2022. The website
207 ClinicalTrials.gov was searched for additional clinical trials. The search terms used were
208 “PARP-inhibitor”, “chemotherapy” and “combination”. To identify only randomised
209 controlled trials during the search, we used the format of ‘Cochrane Highly Sensitive Search
210 Strategy’ [44]. The reference lists of identified articles were also interrogated to further detect
211 any relevant studies.

212

213 **Eligibility criteria**

214 For progression-free survival (PFS), the inclusion criteria for the meta-analyses were: 1) phase
215 II/III randomised controlled trials, 2) patients with cancer of any origin, 3) available biomarker
216 data 4), patients were treated with PARP inhibitors in combination with chemotherapy in the
217 experimental arm and chemotherapy plus placebo in the control arm, and 5) available
218 information on PFS.

219

220 Exclusion criteria for PFS was studies where data could not be extracted on specified outcomes
221 or DNA repair biomarkers.

222

223 For the meta-analyses of adverse effects, the inclusion criteria were the same as for PFS, except
224 studies did not have to select for DNA repair biomarkers. Additional exclusion criteria for
225 adverse effects were: 1) studies did not report adverse effects, and 2) studies did not report
226 adverse effects as total per treatment arm and was therefore unable to be compared with other
227 studies.

228

229 **Outcomes**

230 The primary outcome was PFS defined as the time from randomisation to disease progression
231 or death. Secondary endpoint was to determine common adverse effects and serious adverse
232 effects (grade 3 and 4) of PARP inhibitors in combination with chemotherapy or chemotherapy
233 alone.

234

235 **Data extraction**

236 Based on inclusion and exclusion criteria, two reviewers independently identified studies and
237 the following data was recorded: first author information, publication year, disease setting,
238 study design, number of patients, DNA repair status of patients, type of intervention/control,
239 therapeutic doses of treatment and control arms, and outcomes of interest including PFS, hazard
240 ratios (HRs) and 95% confidence intervals (CIs), and the number of each of the selected adverse
241 effects. In papers with multiple measures of DNA repair deficiency, we extracted data from
242 subgroups that provided the greatest significant difference [15, 45, 46]. In the case where
243 studies only provided Kaplan-Meier curves [47, 48], the software DigitizeIt was used to digitize
244 the graph and extract the individual event and censoring times. The coxph function in R version
245 4.1.2 [49, 50] was used to calculate the HRs and their CIs from the reconstructed datasets. For
246 the analyses of adverse effects, we recorded the number of patients with selected toxicities
247 treated with PARP inhibitor and chemotherapy and total number of patients treated with PARP

248 inhibitor and chemotherapy. We also extracted the number of patients with selected toxicities
249 treated with chemotherapy alone and the total number of patients treated with chemotherapy
250 alone.

251

252 **Risk-of-bias assessment**

253 Two investigators independently assessed the quality of the studies included using version 2 of
254 the Cochrane risk of bias tool for randomised trials (RoB 2) [51]. The risk of bias included bias
255 arising due to the randomisation process, bias due to deviations from intended interventions,
256 bias due to missing outcome data, bias in measurement of outcome and bias in selection of the
257 reported result. Each category was judged as high, low or some concerns for risk of bias.
258 Disagreements were resolved through discussion and consensus among the two reviewers.

259

260 **Statistical analysis**

261 HR for PFS and 95% CI were extracted from each study or calculated based on survival curves
262 of included papers. Pooled HRs were calculated by the generic inverse-variance method with
263 a fixed-effects model, except as adjusted below following assessment of heterogeneity.
264 Studies were weighted based on variance. For the analysis of risk of an adverse effect, patients
265 with adverse effects assigned to the PARP inhibitor and chemotherapy arm were compared
266 with those assigned to the chemotherapy alone control arm in the same trial for the calculation
267 of risk difference.

268

269 Statistical heterogeneity was assessed using a Chi-squared (χ^2) test and inconsistency index
270 (I^2) test. A fixed effects model was used when I^2 value was less than 50%. Above 50%, a
271 random effects model was used.


272

273 A forest plot was generated to visualise each study and pooled analysis. The weight of each
274 study was represented as a square. CIs of each study were indicated as a line across the square.
275 The pooled HR or risk difference was represented as a diamond. A p-value of < 0.05 was
276 considered significant.

277 **RESULTS**

278 **Study selection and characteristics for analysis of PFS**

279



280 **Figure 3. PRISMA flow diagram to identify included studies. PFS: progression-free**
281 **survival.**

282

283 For examining the endpoint of PFS, 9 studies were included following the literature search.

284 The PRISMA flow diagram summarises the process of identifying studies (**Figure 3**). The flow

285 chart presents number of studies identified, screened, included, and excluded, and the reasons

286 for exclusion. Title and abstract screening identified 39 possible studies. Of these, 21 studies

287 were excluded because of the following reasons: did not investigate PARP inhibitors combined

288 with chemotherapies (immunotherapies, angiogenesis therapies), were not phase II/III

289 randomised controlled trials (phase I/II safety trials), or only investigated DNA repair deficient
290 (BRCA-mutated) cohorts. After full-text evaluation, 9 studies were excluded because of the
291 following reasons: no data on DNA repair status of patients, unable to extract HR from data
292 provided, data on PFS not available, or reporting of different endpoints of the same clinical
293 trial across multiple publications (trials excluded [20, 52]) The risk-of-bias assessment of the
294 included studies is presented in **Supplementary Figure 1**. Two studies raised concerns about
295 the randomisation process and outcome measurements due to lack of information about the
296 study, but no studies were excluded.

297

298 The total sample size of the included studies for PFS analysis was 2,084 patients. All included
299 studies reported the effect of PARP inhibitors in combination with chemotherapy versus
300 chemotherapy alone in terms of PFS [15, 45-48, 53-56]. Three studies recruited patients with
301 ovarian cancer, two with breast cancer, two with small cell lung cancer, one with gastric cancer
302 and one with melanoma. The main characteristics of included studies are listed in **Table 2**.

303

304 Results were stratified for DNA repair status (deficient or competent). A patient was considered
305 DNA repair deficient if they had an alteration (mutation, loss, or gain) of a gene involved in
306 DNA repair that has been demonstrated to render increased sensitivity to PARP inhibitors.
307 These included *BRCA1*, *BRCA2*, ATM, SFLN11 and ERCC1. Alternatively, a patient was
308 deemed DNA repair deficient if they were greater than cut-off of 30% on the BRCAPRO test,
309 or greater than 42 on ‘HRD-score’ (Table 1).

310

311 A patient was deemed DNA repair competent if their cancer lacked alterations in the DNA
312 repair marker in the study. Some studies used multiple markers of DNA repair status, and the
313 marker used with respect to each study is specified in the following analyses. After these


314 considerations, 717 patients were DNA repair deficient, and 1,367 patients were DNA repair
315 competent for the purpose of the meta-analysis.

316 **Table 1. Markers of DNA repair deficiency.**

Biomarker	Method of measurement	Cut-off / Discriminating factor
<i>BRCA</i>	DNA	Documented deleterious <i>BRCA1/2</i> mutation, Myriad BRACAnalysis CDx or BRCAPRO score of > 30% (this is an algorithm that predicts whether a person has inherited a <i>BRCA</i> gene mutation)
HRD-score	DNA	HRD-score of > 42
SLFN11	IHC	H-score ≥ 1
ATM	IHC	A clinical status of ATM-positive was assigned to cases with 25% or more gastric cancer cells exhibiting nuclear staining (of weak, moderate, or strong staining intensity) and an ATM-negative status to cases with less than 25% nuclear staining.
ERCC1	IHC	Expression of ERCC1 was defined by immunohistochemistry scores as high (2+, 3+) or low (0, 1+)

317 HRD-score: Homologous recombination deficiency score.

318 **Study selection and characteristics for analysis of adverse effects**



319 **Figure 4. PRISMA flow diagram for identifying studies involving adverse effects of**
 320 **combination PARP inhibitor and chemotherapy.**

321 For examining the endpoint of adverse effects, eight studies were included following the
322 literature search. The PRISMA flow diagram summarises the process of identifying studies
323 (**Figure 4**). To identify these studies, we screened the literature using the same key words as
324 for the primary meta-analysis but adjusted our inclusion/exclusion criteria to remove the
325 requirement for DNA repair biomarkers. Title and abstract screening identified 39 possible
326 studies. Of these, 21 studies were excluded because of the following reasons: did not
327 investigate PARP inhibitors combined with chemotherapies (immunotherapies, angiogenesis
328 therapies) or were not phase II/III randomised controlled trials (phase I/II safety trials). After
329 full-text evaluation, seven studies were excluded because they did not provide data for adverse
330 effects or were not comparable because they did not report patient totals per treatment arm.
331 Note that four studies from our previous analyses on PFS also reported adverse effects that
332 were able to be combined and compared, as in **Table 2**. Sharma et al [46] did not report adverse
333 effects and the four other studies did not provide data for “any” adverse effects or “Any” grade
334 3/4 adverse effects. Since we were interested in tolerability of combination therapy regardless
335 of underlying DNA repair function, we included an additional seven studies that reported
336 adverse effects associated with combination PARP inhibition and chemotherapy that did not
337 qualify for the meta-analysis on PFS. In total, we found eight studies that reported adverse
338 effects on combination PARP inhibitor and chemotherapy compared to chemotherapy alone
339 (**Table 2**). The risk-of-bias assessment of the included studies is presented in **Supplementary**
340 **Figure 2**. Several studies were not double-blinded or were open label, leading to some
341 concerns of bias, but were not excluded from the analysis.

342
343 The total sample size of the included studies for analysis of adverse effects was 4,498 patients.
344 All included studies reported the adverse effects of PARP inhibitors in combination with
345 chemotherapy vs chemotherapy alone, [15, 16, 45, 53, 56-62]. For analysis of adverse effects,

346 a total of 2,347 patients were analysed in the combination PARP inhibitor and chemotherapy
347 arm and a total of 2,151 patients in the chemotherapy alone arm. The main characteristics of
348 included studies are listed in **Table 2**.


349 **Table 2. Characteristics of included studies.**

Study	Disease setting	Experimental arm	Control arm	DNA repair biomarker	DNA repair deficient	DNA repair competent	PARP inhibitor dose	Chemotherapy dose	Analyses
Coleman 2019 [15]	Metastatic high-grade serous ovarian cancer	Veliparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	<i>BRCA1/2</i> & HRD-score	200	249	Veliparib at a dose of 150 mg twice daily	Carboplatin given at AUC of 6 mg/ml/minute and paclitaxel 175 mg/m ²	PFS and AE
Kummar 2015 [47]	Primary high-grade serous ovarian cancer	Veliparib + Cyclophosphamide	Cyclophosphamide	BRCAPRO score	28	25	Veliparib 60mg once daily	Cyclophosphamide 50mg once daily	PFS
Oza 2015 [56]	Primary high-grade serous ovarian cancer	Olaparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	<i>BRCA1/2</i>	41	66	Olaparib 200mg twice daily	Paclitaxel 175 mg/m ²	PFS and AE
Geyer 2022 [54]	Primary triple-negative breast cancer	Veliparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	<i>BRCA1/2</i>	70	406	Veliparib 50mg twice daily	Carboplatin at AUC of 6 mg/ml/min and paclitaxel 80 mg/m ²	PFS
Sharma 2020 [46]	Metastatic triple-negative breast cancer	Veliparib + Cisplatin	Cisplatin	<i>BRCA1/2</i> & HRD-score	101	110	Veliparib 300mg twice daily	Cisplatin 75mg/m ²	PFS
Dieras 2020 [57]	Metastatic breast cancer	Veliparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	<i>BRCA1/2</i>	509	N/A	Veliparib 120mg twice daily	Carboplatin given at AUC of 6mg/mL/min and paclitaxel 80mg/m ²	AE
Han 2020 [58]	Metastatic breast cancer	Veliparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	<i>BRCA1/2</i>	294	N/A	Veliparib 40mg twice daily	Carboplatin given at AUC 6mg/mL/min and paclitaxel 175mg/m ²	AE
Pietanza 2018 [48]	Metastatic small cell lung cancer	Veliparib + Temozolomide	Temozolomide	SLFN11	25	23	Veliparib 40mg twice daily	Temozolomide 200 mg/m ²	PFS
Byers 2021 [53]	Metastatic small cell lung cancer	Veliparib + Carboplatin/Etoposide	Carboplatin/Etoposide	SLFN11	47	43	Veliparib 240 mg twice daily	Carboplatin given at AUC of 5 mg/mL/min and etoposide 100 mg/m ²	PFS and AE
Govindan 2022 [60]	Metastatic non-small cell lung cancer	Veliparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	N/A	595	N/A	Veliparib 120mg twice daily	Carboplatin given at AUC 6mg/mL/min and paclitaxel 200mg/m ²	AE

Ramalingam 2021 [16]	Metastatic squamous non-small cell lung cancer	Veliparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	N/A	970	N/A	Veliparib 120mg twice daily	Carboplatin given at AUC 6mg/mL/min and paclitaxel 200mg/m ²	AE
Liu 2018 [45], Bang 2017 [20]	Metastatic gastric cancer	Olaparib + Paclitaxel	Paclitaxel	ATM	76	324	Olaparib 100 mg twice daily	Paclitaxel 80 mg/m ²	PFS and AE
Middleton 2015 [55]	Metastatic melanoma	Veliparib + Temozolomide	Temozolomide	ERCC1	129	121	Veliparib 40 mg twice daily	Temozolomide 150 mg/m ²	PFS

350 HRD-score: homologous recombination deficiency score; PFS: progression-free survival; AE: adverse effect. Studies are organised based on
351 cancer subtype.

352 **DNA REPAIR DEFICIENT PATIENTS SHOW BENEFIT IN PFS, BUT DNA**
 353 **REPAIR COMPETENT PATIENTS DO NOT**



354
 355 **Figure 5. Comparative effects of combination PARP inhibitor and chemotherapy vs**
 356 **chemotherapy alone in A) DNA repair deficient patients (n=717) and in B) DNA repair**
 357 **competent patients (n=1,367). Results were presented as individual and pooled hazard**
 358 **ratio (HR) with 95% confidence interval (CI). SE: standard error; IV: inverse-variance.**
 359
 360 To evaluate the effect of PARP inhibitor in combination with chemotherapy in DNA repair
 361 deficient patients, we conducted a pooled analysis to compare the PFS between PARP inhibitor
 362 in combination with chemotherapy and the chemotherapy alone group. In total, all 9 studies
 363 were pooled for this analysis. For our analysis, a patient was considered DNA repair deficient

364 if they had an alteration of a gene involved in DNA repair that has been demonstrated to render
365 increased sensitivity to PARP inhibitors (Table 1). For Byers (2021) and Pietanza (2018), we
366 considered SLFN11-positive patients as DNA repair deficient, and SLFN11-negative patients
367 as DNA repair competent [52]. For Geyer (2022), Oza (2015) and Kummar (2015), patients
368 with a *BRCA1/2* mutation were considered DNA repair deficient and those with no mutation
369 in *BRCA1/2* were considered DNA repair competent [53,55]. Additionally, in Kummar (2015),
370 patients were considered DNA repair deficient if they had a BRCAPRO score of >30%. For
371 Liu (2018), ATM-negative patients were considered DNA repair deficient and ATM-positive
372 patients were considered DNA repair competent [44]. For Middleton (2015), low ERCC1
373 expression was considered DNA repair deficient and high ERCC1 expression was considered
374 DNA repair competent [54].

375 In the Coleman (2019) and Sharma (2020) studies, there were multiple biomarkers of impaired
376 DNA repair. For analysis of Coleman (2019), we used “BRCA-mutated” (patients who had
377 germline or tissue-based mutations as determined by the Myriad BRCAAnalysis CDx and
378 myChoice homologous recombination deficiency CDx assay, respectively,
379 in *BRCA1* or *BRCA2*) cohort as our “DNA repair deficient” and the “non-homologous
380 recombination deficiency” (no genetic evidence of homologous recombination deficiency)
381 cohort as “DNA repair competent” [15]. For Sharma (2020), patients were classified into
382 “BRCA-like” (included myChoice homologous recombination deficiency score,
383 somatic *BRCA1/2* mutations, *BRCA1* methylation and non-*BRCA1/2* homologous
384 recombination germline mutations) and “non-BRCA-like”. For our analysis, we defined
385 “BRCA-like” as DNA repair deficient, and “non-BRCA-like” as DNA repair competent.

386

387 717 DNA repair deficient patients received either PARP inhibitor in combination with
388 chemotherapy or chemotherapy alone. Pooled analysis on the DNA repair deficient population

389 showed that PARP inhibitor in combination with chemotherapy, compared to chemotherapy
390 alone, was significantly associated with improved PFS (HR:0.52, 95% CI: 0.43-0.63, $p <$
391 0.00001) (**Figure 5A**).

392

393 1,367 DNA repair competent patients were pooled for analysis. No significant difference in
394 PFS was observed in DNA repair competent patients with PARP inhibitor in combination with
395 chemotherapy compared to chemotherapy alone (HR: 0.94, 95% CI: 0.81-1.08, $p = 0.38$)
396 (**Figure 5B**).

397

398 There was some heterogeneity in these studies including DNA repair deficient patients
399 ($\text{Chi}^2=7.16$), although this was non-significant, and the inconsistency score (I^2) was 0%.

400

401 In the subsequent sections we performed subgroup analyses to determine if there were any
402 factors, including cancer subtype, DNA repair biomarker, or therapy subtype, which could be
403 significantly contributing to the heterogeneity of response.

404


405 **1. DNA REPAIR STATUS DICTATES BENEFIT, REGARDLESS OF CANCER** 406 **SUBGROUP**

407 We next analysed response within cancer subtypes to determine if benefit from combination
408 therapy could be mainly attributed to certain cancer subtypes. We pooled studies that had two
409 or more trials investigating the same cancer type. The combination therapy significantly
410 improved PFS in DNA repair deficient patients in ovarian cancer (HR: 0.44, 95% CI: 0.31-
411 0.64, $p < 0.00001$), breast cancer (HR: 0.57, 95% CI: 0.38-0.86, $p = 0.007$) and small cell lung
412 cancer (HR: 0.47, 95% CI: 0.26-0.85, $p = 0.01$) (**Figure 6A(i), B(i), C(i)**). In contrast, DNA


413 repair competent patients had no associated improvement in PFS from the combination therapy
 414 in any of the cancer subtypes (**Figure 6A(ii), B(ii), C(ii)**).

A) Ovarian cancer

(i) DNA repair deficient patients, n=269




(ii) DNA repair competent patients, n=280




B) Breast cancer

(i) DNA repair deficient patients, n=171




(ii) DNA repair competent patients, n=516




C) Small cell lung cancer

(i) DNA repair deficient patients, n=72




(ii) DNA repair competent patients, n=66



415 **Figure 6. Comparative effects of combination PARP inhibitor and chemotherapy vs**
 416 **chemotherapy alone separated by cancer subgroup. A) Ovarian cancers with (i) DNA**

417 repair deficient patients (n=269) and (ii) DNA repair competent patients (n=280). B)
 418 Breast cancers with (i) DNA repair deficient patients (n=171) (ii) DNA repair competent
 419 patients (n=516). C) Small cell lung cancers with (i) DNA repair deficient patients (n=72)
 420 and (ii) DNA repair competent patients (n=66). Results were presented as individual and
 421 pooled hazard ratio (HR) with 95% confidence interval (CI). SE: standard error; IV:
 422 inverse-variance.

423
 424 **2. DNA REPAIR FUNCTION STATUS DICTATES BENEFIT, REGARDLESS OF**
 425 **BIOMARKER SUBGROUP**



426 **Figure 7. Comparative effects of combination PARP inhibitor and chemotherapy vs**
 427 **chemotherapy alone separated by *BRCA* status. A) DNA repair deficient, *BRCA*-like**
 428 **patients (n=440) B) DNA repair competent, non-*BRCA*-like patients (n=856). Results**
 429 **were presented as individual and pooled hazard ratio (HR) with 95% confidence interval**
 430 **(CI). SE: standard error; IV: inverse-variance.**

431 We next looked at pooled biomarkers to explore whether benefit from PARP inhibitor in
 432 combination with chemotherapy was only associated with certain biomarkers of DNA repair

433 function. First, we examined studies that incorporated patients with “*BRCA*-like” biology.
434 These studies included patients that were categorised based on *BRCA1/2* mutation or a
435 surrogate marker to categorise cancers as DNA repair deficient due to a ‘*BRCA*-like’ event.
436 Two papers in this analysis incorporated surrogate *BRCA*-like markers [15, 46]. Sharma (2020)
437 defined the ‘*BRCA*-like’ group with 4 markers: homologous recombination deficiency genomic
438 instability score of > 42 , somatic *BRCA1/2* mutation, *BRCA1* promoter methylation, and
439 germline DNA repair gene mutations other than *BRCA1/2*. Positivity on any 1 of the 4 markers
440 placed a patient in the *BRCA*-like group. ‘Non-*BRCA*-like’ patients included patients that did
441 not have any of the 4 markers above. In Coleman (2019), multiple measures of *BRCA1/2* status
442 were compared including germline *BRCA1/2* mutation (gBRCAmut), and ‘*BRCA*-like’ patients
443 include those that have somatic and germline *BRCA1/2* gene mutations and/or a ‘*BRCA*-like’
444 phenotype based on DNA repair deficiency assays. We extracted data from ‘gBRCAmut’ for
445 the purpose of this subgroup analysis, as Coleman *et al* concluded that it was a better
446 discriminator for improvement in survival based on their analyses.

447
448 *BRCA*-like patients showed significant improvement in PFS with the combination therapy (HR:
449 0.50, 95% CI: 0.38-0.65, $p < 0.00001$) (**Figure 7A**). There was no significant difference in the
450 PFS of non-*BRCA*-like patients with the addition of PARP inhibitor (HR: 0.90, 95% CI: 0.74-
451 1.09, $p = 0.29$) (**Figure 7B**). There was some heterogeneity observed in the analysis of the
452 *BRCA*-like, DNA repair deficient patients ($\text{Chi}^2 = 5.43$, $I^2 = 26\%$) likely due to the variability
453 of definition of “*BRCA*-like” in these studies, although this was not enough to perform a
454 random effects model.

455
456 Both studies of small cell lung cancer were performed with the biomarker SFLN11. High
457 expression of SFLN11 was associated with increased PFS in patients treated with combination

458 therapy (**Figure 6C(i), (ii)**). Patients with absent SFLN11 did not show any improvement in
459 PFS with combination therapy.

460

461 Overall, the *BRCA*-like and SFLN11 biomarkers were both able to discriminate patient
462 populations with an improved PFS when treated with combination therapy.

463


464 **3. INVESTIGATION OF THE BENEFIT ASSOCIATED WITH SPECIFIC PARP** 465 **INHIBITORS OR CHEMOTHERAPIES USED IN COMBINATIONS**

466 We next considered whether the type of PARP inhibitor or the type of chemotherapy could
467 influence the benefit seen in PFS following combination therapy. Two PARP inhibitors were
468 used in these studies, veliparib (7 studies) [15, 46-48, 53-55] and olaparib (2 studies) [45, 56].
469 Notably, there was variability in dosing, scheduling, and length of treatments. Veliparib and
470 olaparib were given twice daily, except for one study where veliparib was given once daily
471 [47]. Doses of veliparib ranged from 20mg to 400mg and olaparib ranged from 100mg to
472 400mg. The length of treatment cycles varied between studies from 14-days to 28-day cycles.
473 The number of cycles patients received also varied from patients receiving 1 cycle of treatment,
474 to patients receiving 30 cycles of treatment.

475


476 A significant benefit to PFS was seen for DNA repair deficient patients treated with
477 combination therapy regardless of the type of PARP inhibitor, whereas no benefit was seen in
478 DNA repair competent patients (**Figure 8**). Even though the conditions of treatment were
479 highly variable, there was little heterogeneity in studies that included veliparib treatment (DNA
480 repair deficient: $\text{Chi}^2=3.42$, DNA repair competent: $\text{Chi}^2=3.99$), and the inconsistency score
481 (I^2) was 0%. Only two studies examined olaparib treatment which probably led to the
482 considerable heterogeneity ($I^2 =72\%$) between those studies as they were conducted on

483 different cancer types with different treatment regimes. Consequently, we applied a random
 484 effects model to this analysis, and to the other analyses of olaparib for consistency.



485 **Figure 8. Comparative effects of combination PARP inhibitor and chemotherapy vs**
 486 **chemotherapy alone separated by type of PARP inhibitor. A) Veliparib in DNA repair**
 487 **deficient patients (n=600) B) Veliparib in DNA repair competent patients (n=977) C)**
 488 **Olaparib in DNA repair deficient patients (n=117) D) Olaparib in DNA repair competent**
 489 **patients (n=390). A) and B) were analysed using fixed effects model. C) and D) were**
 490 **analysed using random effects model. Results were presented as individual and pooled**

491 hazard ratio (HR) with 95% confidence interval (CI). SE: standard error; IV: inverse-
 492 variance.



493
 494 **Figure 9. Comparative effects of combination PARP inhibitor and chemotherapy vs**
 495 **chemotherapy alone separated by type of chemotherapy. A) Platinum-based**
 496 **chemotherapy in (i) DNA repair deficient patients (n=459) and (ii) DNA repair competent**
 497 **patients (n=874). B) Non-platinum-based chemotherapy in (i) DNA repair deficient**
 498 **patients (n=258) and (ii) DNA repair competent patients (n=493). Results were presented**

499 **as individual and pooled hazard ratio (HR) with 95% confidence interval (CI). SE:**
500 **standard error; IV: inverse-variance.**

501
502 The chemotherapy treatment across the 9 trials was highly varied, and included carboplatin,
503 etoposide, paclitaxel, cyclophosphamide, and etoposide. Each trial also used different doses
504 and schedules of chemotherapy treatment. However, the trials could be broadly separated into
505 trials that included platinum-based therapies (carboplatin and cisplatin) and non-platinum
506 therapies (cyclophosphamide, temozolomide and paclitaxel). As DNA repair deficient cancers
507 are frequently more sensitive to platinum-based drugs [63], we considered whether the benefit
508 of combination therapy is altered with this treatment.


509
510 A significant benefit to PFS was seen for DNA repair deficient patients treated with either
511 platinum-based or other combination therapies. There was no improvement to PFS in DNA
512 repair competent patients regardless of whether the chemotherapy included platinum-based
513 drugs (**Figure 9**).

514 **4. ADVERSE EFFECTS: NO OVERALL INCREASE IN THE FREQUENCY OF**
515 **ADVERSE EFFECTS, BUT SIGNIFICANTLY HIGHER GRADE 3/4 EFFECTS**
516 **IN COMBINATION TREATED PATIENTS**


517 Next, we assessed the secondary endpoint of whether the combination of PARP inhibitors
518 and chemotherapy is well tolerated compared to chemotherapy alone. We found eight
519 studies that reported adverse effects on combination PARP inhibitor and chemotherapy
520 compared to chemotherapy alone. In total, we assessed 3,789 patients with reported adverse
521 effects. 1,987 patients were treated with combination PARP inhibitor and chemotherapy
522 and 1,802 patients were treated with chemotherapy alone (**Table 3**).

Study	All adverse effects (PARP inhibitor + chemotherapy vs chemotherapy alone)	Serious Grade 3/4 adverse effects (PARP inhibitor + chemotherapy vs chemotherapy alone)	Adverse effects with >10% greater incidence in combination therapy
Bang 2017 [20]	99.2% (260/262) vs 98% (254/259)	77.9% (204/262) vs 61.8% (160/259)	Any grade: anaemia, neutrophil count decreased Grade 3/4: N/A
Byers 2021 [53]	96.7% (58/60) vs 96.7% (58/60)	81.7% (49/60) vs 68.3% (41/60)	Any grade: pneumonia Grade 3/4: neutropenia, anaemia, thrombocytopenia
Coleman 2019 [15]	100% (377/377) vs 100% (371/371)	88% (332/377) vs 76.8% (285/371)	Any grade: nausea, anaemia thrombocytopenia, vomiting Grade 3/4: anaemia, thrombocytopenia
Dieras 2020 [57]	99.4% (334/336) vs 100% (171/171)	96.4% (324/336) vs 95.3% (163/171)	Any grade: N/A Grade 3/4: infections after neutropenia, hematopoietic thrombocytopenia
Govindan 2022 [60]	97.6% (286/293) vs 96.2% (277/288)	67.6% (198/293) vs 56.3% (162/288)	Any grade: alopecia, peripheral sensory neuropathy Grade 3/4: neutropenia
Han 2018 [58]	100% (93/93) vs 97.9% (94/96)	78.5% (73/93) vs 83.3% (80/96)	Any grade: bone pain, diarrhoea, nausea, upper respiratory tract infection Grade 3/4: N/A
Oza 2015 [56]	100% (81/81) vs 97.3% (73/75)	65.4% (53/81) vs 57.3% (43/75)	Any grade: alopecia, nausea, diarrhoea, headache, peripheral neuropathy, dyspepsia, neutropenia Grade 3/4: N/A
Ramalingam 2021 [16]	95.9% (465/485) vs 95.9% (462/482)	60.2% (292/485) vs 58.3% (281/482)	Any grade: N/A Grade 3/4: N/A


A) All adverse effects, n=3,789



B) Severe grade 3/4 adverse effects, n=3,789



C) Neutropenia grade 3/4 adverse effects, n=3,789



525 **Figure 10. Adverse effects of combination of PARP inhibitor and chemotherapy vs**
 526 **chemotherapy alone. A) All adverse effects B) Severe grade 3/4 adverse effects**
 527 **C) Neutropenia grade 3/4 adverse effects (n=3,789). Results were presented as individual**
 528 **and pooled risk difference with 95% confidence interval (CI). M-H: Mantel-Haenszel.**
 529
 530 Pooled data were stratified for all adverse effects and data was analysed using risk difference.
 531 We note that there are inconsistencies in the reporting of adverse effects (reported variously as
 532 occurring in >5% vs >10% vs >20% of patients), and different adverse effects were reported
 533 in each study. This is likely to have contributed to heterogeneity within the analyses. Our initial

534 analysis demonstrated high heterogeneity in the analysis of grade 3/4 adverse effects ($I^2 =$
535 74%). Consequently, we applied a random effects model to this analysis, and to the other
536 analyses of adverse effects for consistency.

537

538 There was no significant difference in the incidence of all adverse effects between patients
539 treated with combination therapy or chemotherapy alone (RD: 0.00, 95% CI: -0.01-0.01,
540 $p = 0.47$) (**Figure 10A**). However, when looking at more severe side effects, the combination
541 therapy was associated with a significant increase in the incidence of grade 3/4 adverse effects
542 (RD: 0.07, 95% CI: 0.02-0.12, $p = 0.009$) (**Figure 10B**). The high heterogeneity observed with
543 the assessment of grade 3/4 effects led us to perform a more refined analysis on haematological
544 effects, as these were very common and reported with greater consistency among the studies.
545 We chose to investigate neutropenia as the most reported haematological effect. We found that
546 neutropenia had increased incidence with the combination therapy (RD: 0.06, 95% CI: 0.03-
547 0.09, $p = 0.0004$) (**Figure 10C**). The analysis of neutropenia alone did not exhibit high
548 heterogeneity.

549

550 **DISCUSSION**

551 Several PARP inhibitors are approved by Food and Drug Administration (FDA) and European
552 Medicines Agency (EMA) as maintenance therapies following first-line treatments for DNA
553 repair deficient ovarian, breast, pancreatic and prostate cancers. PARP inhibitors are yet to be
554 approved for use as part of short-term therapeutic regimens with curative intent in any
555 malignancy. However, this is an intense area of clinical investigation with a multitude of
556 clinical trials assessing the potential of combining PARP inhibitors with immunotherapies,
557 radiation therapy, chemotherapies, and other therapies to improve rates of success of those
558 therapeutic regimes.

559

560 Our results, combining nine studies and 2,084 patients across several cancer subtypes,
561 demonstrates that patients with an identifiable DNA repair deficiency may gain an
562 improvement in PFS if PARP inhibitors are combined with chemotherapy as a line of therapy.
563 In contrast, DNA repair competent patients did not show any additional benefit (**Figure 5**).
564 Furthermore, we found that benefit for DNA repair deficient patients was associated with
565 combination therapy in all cancer subtypes investigated including ovarian, breast and small cell
566 lung cancers (**Figure 6**). We considered whether certain biomarkers (*BRCA*-like, *SLFN11*)
567 would have differences in their associated benefit, but found similar benefit was seen with the
568 combination therapy in DNA repair deficient but not DNA repair competent patients regardless
569 of the biomarker (**Figure 7**). We observed that the benefit for DNA repair deficient patients
570 was not influenced by either the type of PARP inhibitor (veliparib, olaparib) or chemotherapy
571 (platinum-based, non-platinum-based) (**Figure 8&9**).

572
573 All subgroup analyses supported the same conclusion that improved PFS from combination
574 therapy was only associated with DNA repair deficiency status. However, there were several
575 limitations to our study. First, each study involved different chemotherapies, PARP inhibitor
576 and dosing regimens. This likely contributed to the heterogeneity observed across some of the
577 subgroup analyses and analysis of adverse effects. To address issues of heterogeneity, we
578 applied a random effects model to analyses where heterogeneity was greater than 50%, but the
579 addition of more studies would be informative. A second limitation of this meta-analysis is that
580 we were unable to assess the impact of treatment and DNA repair deficiency status on overall
581 survival, as those data are not yet available due to the immaturity of trials in this area.

582
583 While this meta-analysis did not show any benefit in DNA repair competent cancers, it should
584 also be considered whether the most optimal PARP inhibitors and chemotherapies were used

585 in the combination therapies in these trials. Of note, both of the PARP inhibitors used in these
586 analysed studies, veliparib and olaparib, have weak PARP trapping ability [64, 65]. Synergy
587 with chemotherapy has been suggested to be dependent upon PARP trapping [27], and the
588 combination of chemotherapy with efficient PARP trappers such as talazoparib [66] may
589 provide greater synergistic effects. A drawback of PARP inhibitors with higher trapping ability,
590 is the potential for greater challenges with toxicity. However, a recent phase I study
591 investigated the safety of combined talazoparib and carboplatin/paclitaxel and found that the
592 combination is feasible with an intermittent, lower dose schedule of talazoparib and appropriate
593 supportive care [67]. Further investigation into the dosing regimen may assist in enhancing
594 anti-tumour efficacy whilst improving tolerability.

595

596 PARP inhibitors are only approved for DNA repair deficient cancers. The exception is
597 niraparib, which is approved as first line maintenance therapy regardless of homologous
598 recombination deficiency status for ovarian cancers that have shown a response to platinum
599 therapies. Response to platinum salts is correlated with the presence of homologous
600 recombination deficiency [68], and has high penetrance in ovarian cancer with up to 69%
601 classified as homologous recombination deficient [69]. Thus, it may be that the high penetrance
602 of homologous recombination deficiency in ovarian cancers leads to a more general
603 susceptibility to PARP inhibitors, alone or in combination with chemotherapies. Interestingly,
604 from our subgroup analysis of ovarian cancers without a homologous recombination
605 deficiency, there was an overall weighted average effect of 1.38 with combination therapy,
606 although this was not significant ($p < 0.17$; HR: 0.83; CI 0.64-1.08). Since this subgroup analysis
607 only includes 340 patients over three studies, the addition of further studies may indicate
608 benefit for combination PARP inhibitors and chemotherapy in ovarian cancer patients that do
609 not have canonical homologous recombination deficiency indicators such as *BRCA1/BRCA2*

610 mutation. This should be re-examined if more clinical trials are reported on PARP
611 inhibitor/chemotherapy combinations for ovarian cancer.

612

613 A major consideration in this analysis is that the definition of DNA repair deficiency is highly
614 heterogeneous, with individual clinical trials using different methods and cut-offs to assess a
615 patient's DNA repair deficiency status. This raises the question of whether there should be a
616 uniform definition of DNA repair deficiency, or if each cancer subtype will require its own
617 specific biomarkers. SFLN11 is an emerging biomarker of PARP inhibitor sensitivity, but
618 unlike mutations to homologous recombination pathway genes it does not appear to be
619 associated with the presence of genomic scars [22]. Instead SFLN11 is actively recruited to
620 sites of DNA damage to inhibit homologous recombination [70], and its high expression is
621 correlated with PARP inhibitor sensitivity [22]. This seems to be particularly relevant for small
622 cell lung cancer [53], but a retrospective analysis of 110 ovarian cancers treated with PARP
623 inhibitor suggests there could be broader application [71]. In that study, *BRCA*-wildtype
624 ovarian cancer patients with high SFLN11 showed non-significant improvements in olaparib
625 response compared to SFLN11 low patients [71]. Overall, each of these biomarkers should be
626 assessed in each cancer setting for its frequency, overlap with other DNA repair biomarkers,
627 and its potential as an indicator of PARP inhibitor sensitivity.

628

629 An area that was not explored with this meta-analysis was whether non-DNA repair markers
630 may be predictive of benefit from combination PARP inhibitors and chemotherapy. In the
631 study of Ramalingam *et al* [16] the LP52, a 52 gene panel that was first generated to
632 differentiate squamous non-small cell lung cancer subtypes, was predictive of a better response
633 to veliparib in combination with carboplatin/paclitaxel. A similar, but non-significant, trend
634 was seen in the study of Govindan *et al* on veliparib with carboplatin/paclitaxel versus

635 physician's choice of standard chemotherapy in advanced non-squamous non-small cell lung
636 cancer [60]. Thus, alternative markers may provide more guidance for combination therapy,
637 especially in those cancer types without a high penetrance of DNA repair deficiencies.

638

639 Our secondary analysis of the adverse effects associated with combination treatment versus
640 chemotherapy alone revealed that combination therapy had higher associated toxicities. Grade
641 3/4 adverse effects and neutropenia were significantly higher with chemotherapy and PARP
642 inhibitor combination therapy, although there was no increase in overall effects of all grades.
643 A confounding issue was the significant heterogeneity we observed when considering grade
644 3/4 adverse effects (**Figure 10B**). This was most likely due to the differences in criteria used
645 for adverse effects in each clinical trial. Re-analysis of the data for neutropenia alone
646 demonstrated an increased risk with combination therapy, and the data showed very little
647 heterogeneity for this sub-analysis. Data from further clinical trials are needed to resolve
648 whether other haematological and non-haematological side-effects are significantly associated
649 with the combination of chemotherapy and PARP inhibitors. Despite these side-effects, it is
650 important to note that the PFS benefit with the combination of PARP inhibitor and
651 chemotherapy was achieved despite dose modifications occurring in most of the studies. Most
652 studies found that the combination therapy had a manageable toxicity profile.

653

654 In conclusion, DNA repair deficiency associates with improved PFS following combination
655 PARP inhibitor and chemotherapy compared to chemotherapy alone, but there is no associated
656 benefit for DNA repair competent patients. Despite the potential to improve outcome for DNA
657 repair deficient patients, the benefit must be weighed against the increase in associated
658 toxicities. Results show that combined PARP inhibitor and chemotherapy are associated with
659 an increase in severe adverse effects, particularly neutropenia, compared to chemotherapy

660 alone. Previous meta-analyses have shown that haematological side-effects are very common
661 with PARP inhibitors [72], and this effect is likely to be compounded with the addition of
662 chemotherapy. Whilst this may prevent the effective use of these combinations, there are
663 existing strategies to manage haematological side-effects, such as dose interruptions, dose
664 reductions and in appropriate patients, treat with granulocyte colony- stimulating factors to
665 help stimulate neutrophil production [73, 74], and these could be applied in the combination
666 setting along with close monitoring of patients. To our knowledge, this is the first synthesised
667 analysis of the efficacy of combination PARP inhibitor and chemotherapy across multiple
668 malignancies to demonstrate that this benefit is dependent upon the presence of a DNA repair
669 biomarker.

670 **REFERENCES**

- 671 1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, Bray F:
672 **Cancer statistics for the year 2020: An overview.** *International journal of cancer*
673 2021.
- 674 2. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P,
675 Krie A, Piccioni DE, Miller VA *et al*: **Molecular profiling of cancer patients**
676 **enables personalized combination therapy: the I-PREDICT study.** *Nat Med* 2019,
677 **25(5):744-750.**
- 678 3. Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA: **PARP Inhibitors: Extending**
679 **Benefit Beyond BRCA-Mutant Cancers.** *Clin Cancer Res* 2019, **25(13):3759-3771.**
- 680 4. Yousefzadeh M, Henpita C, Vyas R, Soto-Palma C, Robbins P, Niedernhofer L: **DNA**
681 **damage—how and why we age?** *Elife* 2021, **10:e62852.**
- 682 5. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL,
683 Meier W, Shapira-Frommer R, Safra T *et al*: **Olaparib maintenance therapy in**
684 **patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned**
685 **retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.**
686 *The Lancet Oncology* 2014, **15(8):852-861.**
- 687 6. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W,
688 Tung N, Armstrong A *et al*: **Olaparib for Metastatic Breast Cancer in Patients**
689 **with a Germline BRCA Mutation.** *N Engl J Med* 2017, **377(6):523-533.**
- 690 7. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO,
691 Hochhauser D, Arnold D, Oh DY *et al*: **Maintenance olaparib for germline BRCA-**
692 **mutated metastatic pancreatic cancer.** *New Engl J Med* 2019, **381(4):317-327.**
- 693 8. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N,
694 Weberpals JI, Clamp A, Scambia G *et al*: **Rucaparib maintenance treatment for**

- 695 **recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a**
696 **randomised, double-blind, placebo-controlled, phase 3 trial.** *Lancet* 2017,
697 **390(10106):1949-1961.**
- 698 9. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L,
699 Yerushalmi R, Mina LA, Martin M *et al*: **Talazoparib in Patients with Advanced**
700 **Breast Cancer and a Germline BRCA Mutation.** *N Engl J Med* 2018, **379(8):753-**
701 **763.**
- 702 10. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M,
703 Ledermann JA, Lorusso D, Vergote I *et al*: **Niraparib Maintenance Therapy in**
704 **Platinum-Sensitive, Recurrent Ovarian Cancer.** *N Engl J Med* 2016,
705 **375(22):2154-2164.**
- 706 11. Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner
707 Hendrickson AE, Azodi M, DiSilvestro P, Oza AM *et al*: **Niraparib monotherapy**
708 **for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label,**
709 **single-arm, phase 2 trial.** *The Lancet Oncology* 2019, **20(5):636-648.**
- 710 12. Arun BK, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL,
711 Bell-McGuinn KM, Bach BA, Kundu MG *et al*: **Efficacy and safety of first-line**
712 **veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline**
713 **BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.**
714 *European journal of cancer (Oxford, England : 1990)* 2021, **154:35-45.**
- 715 13. Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P,
716 Waters J, Berek JS, Woie K, Oza AM *et al*: **Niraparib Maintenance Therapy in**
717 **Patients With Recurrent Ovarian Cancer After a Partial Response to the Last**
718 **Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.** *J Clin Oncol*
719 **2019, 37(32):2968-2973.**

- 720 14. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza
721 MR, McCormick C, Lorusso D, Hoskins P, Freyer G *et al*: **Niraparib in Patients**
722 **with Newly Diagnosed Advanced Ovarian Cancer**. *N Engl J Med* 2019,
723 **381(25):2391-2402**.
- 724 15. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M,
725 Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL *et al*: **Veliparib with First-**
726 **Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer**. *N Engl J*
727 *Med* 2019, **381(25):2403-2415**.
- 728 16. Ramalingam SS, Novello S, Guclu SZ, Bentsion D, Zvirbule Z, Szilasi M, Bernabe R,
729 Syrigos K, Byers LA, Clingan P *et al*: **Veliparib in Combination With Platinum-**
730 **Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell**
731 **Lung Cancer: A Randomized, Multicenter Phase III Study**. *J Clin Oncol* 2021,
732 **39(32):3633-3644**.
- 733 17. Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM,
734 Dworkin L, Nemunaitis J: **Homologous recombination proficiency in ovarian and**
735 **breast cancer patients**. *BMC Cancer* 2021, **21(1):1154**.
- 736 18. Jette NR, Kumar M, Radhamani S, Arthur G, Goutam S, Yip S, Kolinsky M,
737 Williams GJ, Bose P, Lees-Miller SP: **ATM-Deficient Cancers Provide New**
738 **Opportunities for Precision Oncology**. *Cancers (Basel)* 2020, **12(3)**.
- 739 19. Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C,
740 Jain S, Varughese M *et al*: **Olaparib in patients with metastatic castration-**
741 **resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a**
742 **multicentre, open-label, randomised, phase 2 trial**. *The Lancet Oncology* 2020,
743 **21(1):162-174**.

- 744 20. Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA
745 *et al*: **Olaparib in combination with paclitaxel in patients with advanced gastric**
746 **cancer who have progressed following first-line therapy (GOLD): a double-**
747 **blind, randomised, placebo-controlled, phase 3 trial.** *The Lancet Oncology* 2017,
748 **18(12):1637-1651.**
- 749 21. Xie K, Ni X, Lv S, Zhou G, He H: **Synergistic effects of olaparib combined with**
750 **ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer.** *Oncol Lett*
751 2021, **21(5):365.**
- 752 22. Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, De
753 Stanchina E, Teicher BA, Riaz N, Powell SN: **PARP Inhibitor Activity Correlates**
754 **with SLFN11 Expression and Demonstrates Synergy with Temozolomide in**
755 **Small Cell Lung CancerSLFN11 Predicts PARP Inhibitor Response in SCLC.**
756 *Clin Cancer Res* 2017, **23(2):523-535.**
- 757 23. Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrourpour F, Fan Y,
758 Bara RO, Feng Y *et al*: **Dynamic variations in epithelial-to-mesenchymal**
759 **transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and**
760 **cisplatin in small cell lung cancer.** *Oncotarget* 2017, **8(17):28575-28587.**
- 761 24. Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A,
762 Khodos I, de Stanchina E, Nguyen T *et al*: **Chemosensitive Relapse in Small Cell**
763 **Lung Cancer Proceeds through an EZH2-SLFN11 Axis.** *Cancer Cell* 2017,
764 **31(2):286-299.**
- 765 25. Yusoh NA, Ahmad H, Gill MR: **Combining PARP Inhibition with Platinum,**
766 **Ruthenium or Gold Complexes for Cancer Therapy.** *ChemMedChem* 2020,
767 **15(22):2121-2135.**

- 768 26. Lu Y, Liu Y, Pang Y, Pacak K, Yang C: **Double-barreled gun: Combination of**
769 **PARP inhibitor with conventional chemotherapy.** *Pharmacol Ther* 2018, **188**:168-
770 175.
- 771 27. Dréan A, Lord CJ, Ashworth A: **PARP inhibitor combination therapy.** *Crit Rev*
772 *Oncol/Hematol* 2016, **108**:73-85.
- 773 28. Fankhauser M, Bechmann N, Lauseker M, Goncalves J, Favier J, Klink B, William D,
774 Geldon L, Maurer J, Spöttl G *et al*: **Synergistic Highly Potent Targeted Drug**
775 **Combinations in Different Pheochromocytoma Models Including Human Tumor**
776 **Cultures.** *Endocrinology* 2019, **160**(11):2600-2617.
- 777 29. Cao X, Lu Y, Liu Y, Zhou Y, Song H, Zhang W, Davis D, Cui J, Hao S, Jung J *et al*:
778 **Combination of PARP inhibitor and temozolomide to suppress chordoma**
779 **progression.** *Journal of Molecular Medicine* 2019, **97**(8):1183-1193.
- 780 30. Shen H-Y, Tang H-L, Zheng Y-H, Feng J, Dong B-X, Chen X-Q: **The PARP1**
781 **Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with**
782 **Temozolomide for Antimyeloma Effects.** *Journal of oncology* 2022, **2022**:2800488.
- 783 31. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz
784 VD, Cox BF, DeWeese TL, Dillehay LE *et al*: **ABT-888, an Orally Active**
785 **Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents**
786 **in Preclinical Tumor Models.** *Clin Cancer Res* 2007, **13**(9):2728-2737.
- 787 32. Tentori L, Leonetti, C., Scarsella, M., Muzi, A., Mazzon, E., Vergati, M., Forini, O.,
788 Lapidus, R., Xu, W., Dorio, A.S., Zhang, J., Cuzzocrea, S. and Graziani, G.:
789 **Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced**
790 **intestinal damage and enhances irinotecan/temozolomide efficacy against colon**
791 **carcinoma.** *The FASEB Journal* 2006, **20**(10):1709-1711.

- 792 33. Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y: **Rationale for**
793 **Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with**
794 **Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic**
795 **Inhibition.** *J Pharmacol Exp Ther* 2014, **349**(3):408-416.
- 796 34. Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM:
797 **Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug**
798 **Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-**
799 **Negative Breast Cancer.** *Clin Cancer Res* 2017, **23**(13):3405-3415.
- 800 35. Genter Williams SM, Kuznicki AM, Andrade P, Dolinski BM, Elbi C, O'Hagan RC,
801 Toniatti C: **Treatment with the PARP inhibitor, niraparib, sensitizes colorectal**
802 **cancer cell lines to irinotecan regardless of MSI/MSS status.** *Cancer Cell*
803 *International* 2015, **15**(1):14.
- 804 36. Davidson D, Wang Y, Aloyz R, Panasci L: **The PARP inhibitor ABT-888**
805 **synergizes irinotecan treatment of colon cancer cell lines.** *Invest New Drugs* 2013,
806 **31**(2):461-468.
- 807 37. Tahara M, Inoue T, Sato F, Miyakura Y, Horie H, Yasuda Y, Fujii H, Kotake K,
808 Sugano K: **The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in**
809 **Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA**
810 **Double-Strand Breaks.** *Mol Cancer Ther* 2014, **13**(5):1170-1180.
- 811 38. Bowman KJ, Newell DR, Calvert AH, Curtin NJ: **Differential effects of the poly**
812 **(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II**
813 **inhibitor cytotoxicity in L1210 cells in vitro.** *Br J Cancer* 2001, **84**(1):106-112.
- 814 39. Eetezadi S, Evans JC, Shen Y-T, De Souza R, Piquette-Miller M, Allen C: **Ratio-**
815 **Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and**
816 **Spheroid Models of Ovarian Cancer.** *Mol Pharm* 2018, **15**(2):472-485.

- 817 40. MIYAMOTO K, MINEGAKI T, TANAHASHI M, YAMAMOTO A, MORIYAMA
818 Y, WADA A, MATSUMOTO A, OTA K, TANAKA M, MASUDA U *et al*:
819 **Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal**
820 **Squamous Cell Carcinoma Cell Lines.** *Anticancer Res* 2019, **39**(4):1813-1820.
- 821 41. Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M,
822 Yanagida S, Iwamoto M, Kiyokawa T *et al*: **Paclitaxel sensitizes homologous**
823 **recombination-proficient ovarian cancer cells to PARP inhibitor via the**
824 **CDK1/BRCA1 pathway.** *Gynecol Oncol* 2022, **168**:83-91.
- 825 42. Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, Wang L, El-Rayes B, Shu HK:
826 **In vitro and in vivo enhancement of chemoradiation using the oral PARP**
827 **inhibitor ABT-888 in colorectal cancer cells.** *Int J Radiat Oncol Biol Phys* 2013,
828 **86**(3):469-476.
- 829 43. Matulonis U, Monk B: **PARP inhibitor and chemotherapy combination trials for**
830 **the treatment of advanced malignancies: does a development pathway forward**
831 **exist?** *Ann Oncol* 2017, **28**(3):443-447.
- 832 44. Lefebvre C GJ, Briscoe S, Featherstone R, Littlewood A, Marshall C, Metzendorf M-
833 I, Noel-Storr A, Paynter R, Rader T, Thomas J, Wieland LS: **Technical Supplement**
834 **to Chapter 4: Searching for and selecting studies.** *Cochrane Handbook for*
835 *Systematic Reviews of Interventions Version 63 (updated February 2022)* 2022, **In:**
836 **Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA**
837 **(eds).**
- 838 45. Liu YZ, Hodgson D, Locker G, Lai Z, Balcerzak D, Sharpe A, Barrett JC, Orr M,
839 Gutjahr TS, Dougherty B *et al*: **Olaparib plus paclitaxel sensitivity in biomarker**
840 **subgroups of gastric cancer.** *Ann Oncol* 2018, **29**:25-26.

- 841 46. Sharma P, Rodler E, Barlow WE, Gralow J, Huggins-Puhalla SL, Anders CK,
842 Goldstein LJ, Brown-Glaberman UA, Huynh TT, Szyarto CS *et al*: **Results of a**
843 **phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative**
844 **breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG**
845 **S1416).** *Journal of Clinical Oncology* 2020, **38**(15).
- 846 47. Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ,
847 Villalona-Calero MA, Morgan RJ, Jr., Szabo PM, Youn A *et al*: **Randomized Trial**
848 **of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian,**
849 **Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian**
850 **Cancer.** *Clin Cancer Res* 2015, **21**(7):1574-1582.
- 851 48. Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko
852 TK, Woo KM, Cardnell RJ, Fujimoto J *et al*: **Randomized, Double-Blind, Phase II**
853 **Study of Temozolomide in Combination With Either Veliparib or Placebo in**
854 **Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.** *J Clin*
855 *Oncol* 2018, **36**(23):2386-2394.
- 856 49. T T: **A package for Survival Analysis in R.** In., vol. R package version 3.3-1; 2022.
- 857 50. Team RC: **A Language and Environment for Statistical Computing.** In. R
858 Foundation for Statistical Computing; 2021.
- 859 51. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ,
860 Cheng HY, Corbett MS, Eldridge SM *et al*: **RoB 2: a revised tool for assessing risk**
861 **of bias in randomised trials.** *BMJ* 2019, **366**:14898.
- 862 52. Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA,
863 Birrer MJ, Moore KN, Spirtos NM, Shahin MS *et al*: **Impact of homologous**
864 **recombination status and responses with veliparib combined with first-line**

- 865 **chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.**
866 *Gynecol Oncol* 2022, **164**(2):245-253.
- 867 53. Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, Owonikoko TK, Groen
868 HJM, Gay CM, Fujimoto J *et al*: **Veliparib in combination with carboplatin and**
869 **etoposide in patients with treatment-Naive extensive-stage small cell lung cancer:**
870 **A phase 2 randomized study.** *Clin Cancer Res* 2021, **27**(14):3884-3895.
- 871 54. Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O'Shaughnessy J, Maag D,
872 Untch M, Golshan M, Lorenzo JP *et al*: **Long-term efficacy and safety of addition**
873 **of carboplatin with or without veliparib to standard neoadjuvant chemotherapy**
874 **in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a**
875 **randomized phase III trial.** *Ann Oncol* 2022, **33**(4):384-394.
- 876 55. Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, Chyla B,
877 Jiang F, McKeegan E, Mostafa NM *et al*: **Randomized phase II study evaluating**
878 **veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.**
879 *Ann Oncol* 2015, **26**(10):2173-2179.
- 880 56. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N,
881 Špaček J, Vuylsteke P, Hirte H *et al*: **Olaparib combined with chemotherapy for**
882 **recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.** *The*
883 *Lancet Oncology* 2015, **16**(1):87-97.
- 884 57. Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL,
885 Bondarenko I, Campone M, Jakobsen EH *et al*: **Veliparib with carboplatin and**
886 **paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a**
887 **randomised, double-blind, placebo-controlled, phase 3 trial.** *The Lancet Oncology*
888 2020, **21**(10):1269-1282.

- 889 58. Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I,
890 Citrin D, Campone M, Telli ML *et al*: **Veliparib with temozolomide or**
891 **carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with**
892 **BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.**
893 *Ann Oncol* 2018, **29**(1):154-161.
- 894 59. Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J,
895 Amillano K, Bonnefoi H, Casas A, Manso L *et al*: **SOLTI NeoPARP: a phase II**
896 **randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel**
897 **alone as neoadjuvant therapy in patients with triple-negative breast cancer.**
898 *Breast Cancer Res Treat* 2015, **154**(2):351-357.
- 899 60. Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T,
900 Lee KH *et al*: **Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's**
901 **Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous**
902 **Non-Small Cell Lung Cancer.** *Clin Lung Cancer* 2022, **23**(3):214-225.
- 903 61. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman
904 BM, Bradley C: **Iniparib plus chemotherapy in metastatic triple-negative breast**
905 **cancer.** *N Engl J Med* 2011, **364**(3):205-214.
- 906 62. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M,
907 Robert N, Hellerstedt B, Saleh M, Richards P *et al*: **Phase III study of iniparib plus**
908 **gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with**
909 **metastatic triple-negative breast cancer.** *J Clin Oncol* 2014, **32**(34):3840-3847.
- 910 63. Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry
911 WT, Winer EP, Tung NM *et al*: **Homologous Recombination Deficiency (HRD)**
912 **Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in**

- 913 **Patients with Triple-Negative Breast Cancer.** *Clin Cancer Res* 2016, **22**(15):3764-
914 3773.
- 915 64. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S,
916 Pommier Y: **Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.**
917 *Cancer Res* 2012, **72**(21):5588-5599.
- 918 65. Thomas A, Murai J, Pommier Y: **The evolving landscape of predictive biomarkers**
919 **of response to PARP inhibitors.** *The Journal of Clinical Investigation* 2018,
920 **128**(5):1727-1730.
- 921 66. Rudolph J, Jung K, Luger K: **Inhibitors of PARP: Number crunching and**
922 **structure gazing.** *Proceedings of the National Academy of Sciences* 2022,
923 **119**(11):e2121979119.
- 924 67. Leal TA, Sharifi MN, Chan N, Wesolowski R, Turk AA, Bruce JY, O'Regan RM,
925 Eickhoff J, Barroilhet LM, Malhotra J *et al*: **A phase I study of talazoparib (BMN**
926 **673) combined with carboplatin and paclitaxel in patients with advanced solid**
927 **tumors (NCI9782).** *Cancer Medicine* 2022, **11**(21):3969-3981.
- 928 68. Ngoi NYL, Tan DSP: **The role of homologous recombination deficiency testing in**
929 **ovarian cancer and its clinical implications: do we need it?** *ESMO Open* 2021,
930 **6**(3):100144.
- 931 69. Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL,
932 Kirchner M, Goldschmid H, Pfarr N *et al*: **Pan-cancer analysis of genomic scar**
933 **patterns caused by homologous repair deficiency (HRD).** *npj Precision Oncology*
934 2022, **6**(1):36.
- 935 70. Mu Y, Lou J, Srivastava M, Zhao B, Feng X-h, Liu T, Chen J, Huang J: **SLFN11**
936 **inhibits checkpoint maintenance and homologous recombination repair.** *EMBO*
937 *Rep* 2016, **17**(1):94-109.

- 938 71. Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P,
939 Rodriguez-Canales J, Angell HK, Ng FSL *et al*: **Retrospective analysis of**
940 **Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA**
941 **damage response.** *Br J Cancer* 2021, **125**(12):1666-1676.
- 942 72. Wang C, Li J: **Haematologic toxicities with PARP inhibitors in cancer patients:**
943 **an up-to-date meta-analysis of 29 randomized controlled trials.** *J Clin Phar Ther*
944 2021, **46**(3):571-584.
- 945 73. Tookman L, Krell J, Nkolobe B, Burley L, McNeish IA: **Practical guidance for the**
946 **management of side effects during rucaparib therapy in a multidisciplinary UK**
947 **setting.** *Therapeutic advances in medical oncology* 2020, **12**:1758835920921980-
948 1758835920921980.
- 949 74. Lustberg MB: **Management of neutropenia in cancer patients.** *Clin Adv Hematol*
950 *Oncol* 2012, **10**(12):825-826.
- 951